Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Utilizing network pharmacology to investigate the probable mechanism of Danshen chuanxiong drug pair in Kawasaki disease

Aiyuan Cai1, Siting Xu1, Jie He2, Meiping Shi1, Lanlin You1, Zhongbin Pan1, Yanxia Zheng3

1Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou City, Guangdong Province 510410,; 2School of Biomedical Engineering, Guangdong Medical University, Dongguan City, Guangdong Province 523808,; 3Department of Pediatrics, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou City, Guangdong Province 510120, China.

For correspondence:-  Yanxia Zheng   Email: zhengyanxiamed@outlook.com

Received: 9 May 2023        Accepted: 7 December 2024        Published: 30 December 2024

Citation: Cai A, Xu S, He J, Shi M, You L, Pan Z, et al. Utilizing network pharmacology to investigate the probable mechanism of Danshen chuanxiong drug pair in Kawasaki disease. Trop J Pharm Res 2024; 23(12):2001-2015 doi: 10.4314/tjpr.v23i12.5

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the primary components and effect of Danshen-Chuanxiong (DS-CX) in the treatment of Kawasaki disease. Methods: Active ingredients of DS-CX and targets of action were screened via the Traditional Chinese Medicine Systematic Pharmacology (TCMSP) and SwissTargetPrediction databases. Targets of Kawasaki disease were queried in OMIM, GeneCards, DRUGBANK, and Disgenet databases, and intersected with drug targets. Protein-protein interaction maps (PPIs) were constructed using STRING database and Cytoscape software, and core genes of Kawasaki disease were screened. Pathway enrichment analyses (DAVID database, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG)) were conducted for DS-CX targeting Kawasaki disease crossover targets. Results: A total of 64 active ingredients and corresponding potential target genes of DS-CX were obtained. Also, 928 human genes related to Kawasaki disease were obtained from OMIM, DRUGBANK, GeneCards and Disgenet databases. Potential target genes of DS-CX was intersected with 928 human Kawasaki disease-related genes, and a total of 55 genes were screened. The PPI network was built using STRING database and Cyotoscape software, and overlapping genes were further screened. A total of 61 active ingredients were screened for their effects on Kawasaki disease-related targets. GOfunction analysis revealed that DS-CX affected Kawasaki disease by positively regulating gene expression. Also, KEGG enrichment analysis found that DS-CX and Kawasaki disease was mainly enriched in pathways involved in cancer. Conclusion: DS-CX regulates core genes (AKT1, IL6, and TP53) and other genes through active ingredients which in turn act on cancer pathway. Thus, DS-CX demonstrates anti-inflammatory and anti-platelet activities and helps blood vessel repair and remodeling in Kawasaki disease. Further studies to validate Danshen and Chuanxiong for the treatment of Kawasaki disease are needed to determine its mechanism of action

Keywords: Danshen-Chuanxiong drug pair, Kawasaki disease, Anti-inflammatory, Antiplatelet, Network pharmacology

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2025; 24: 
1,   2,   3
2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates